TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Microbot Medical ( (MBOT) ) has shared an announcement.
On November 26, 2025, Microbot Medical announced that Emory University Hospital has become the first hospital globally to adopt its LIBERTY Endovascular Robotic System for patient care. This collaboration includes establishing an Endovascular Robotics Program in interventional radiology, marking a significant milestone for Microbot Medical in the surgical robotics field. The LIBERTY system, designed to reduce radiation exposure and physical strain, is set for a full market release in April 2026, aiming to enhance market adoption. This development is expected to support clinicians in delivering precise care for peripheral intervention procedures, reflecting a major advancement in medical robotics.
The most recent analyst rating on (MBOT) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Microbot Medical stock, see the MBOT Stock Forecast page.
More about Microbot Medical
Microbot Medical Inc. is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. The company’s LIBERTY Endovascular Robotic System is the world’s first FDA-cleared single-use, remotely operated robotic solution designed for precision, efficiency, and safety. Microbot is committed to innovation and holds a strong intellectual property portfolio, driving the future of endovascular care.
Average Trading Volume: 3,951,275
Technical Sentiment Signal: Sell
Current Market Cap: $126.3M
See more insights into MBOT stock on TipRanks’ Stock Analysis page.